Author

C. Gallois

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Favezelimab/Pembrolizumab Coformulation Versus Standard-of-Care in PD-L1–Positive Metastatic Colorectal Cancer: The Phase III, Randomized KEYFORM-007 Study

The phase III KEYFORM-007 study (ClinicalTrials.gov identifier: NCT05064059 ) evaluated the efficacy and safety of coformulated favezelimab/pembrolizumab versus standard-of-care (SOC) in PD-L1–positive microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We present re...

N. Segal, Maria Passhak, F. Kose et al. · JCO Oncology Advances · 0 citations

Open access Oct 2026

First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort.

INTRODUCTION Ampullary adenocarcinoma (AC) is a rare malignancy with limited evidence to guide systemic treatment in the metastatic setting. METHODS This post hoc analysis was conducted within the French national prospective FFCD-AC cohort, which enrolled patients undergoing curative-intent resection for localized AC...

E. Vo-Quang, V. Hautefeuille, O. Bouché et al. · European Journal of Cancer · 0 citations